Mark Sheptoff Financial Planning LLC Purchases Shares of 3,500 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Mark Sheptoff Financial Planning LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 3,500 shares of the company’s stock, valued at approximately $57,000.

Several other large investors also recently made changes to their positions in TEVA. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter valued at $28,000. EntryPoint Capital LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth about $30,000. Beach Investment Counsel Inc. PA purchased a new stake in shares of Teva Pharmaceutical Industries in the second quarter worth about $48,000. Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $52,000. Finally, Industrial Alliance Investment Management Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 1st quarter valued at about $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock opened at $17.88 on Thursday. Teva Pharmaceutical Industries Limited has a one year low of $8.06 and a one year high of $19.08. The company’s 50-day simple moving average is $17.65 and its 200-day simple moving average is $16.03. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.03. The firm had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. As a group, research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 24,537 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $17.25, for a total value of $423,263.25. Following the completion of the transaction, the insider now owns 45,060 shares of the company’s stock, valued at $777,285. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.55% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Bank of America raised their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. Finally, Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average target price of $18.89.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.